Loading...
•
Jun 30, 2024
Sangamo Q2 2024 Earnings Report
Reported business highlights and financial results for the second quarter of 2024.
Key Takeaways
Sangamo announced a global license agreement with Genentech, positive results from the Phase 3 AFFINE trial with Pfizer, and encouraging data from the Phase 1/2 STAAR study. The company's net loss was $36.1 million, and revenues were $0.3 million for the quarter.
Entered into a global license agreement with Genentech for epigenetic regulation and capsid delivery.
Pfizer announced positive topline results from Phase 3 AFFINE trial for Hemophilia A gene therapy co-developed with Sangamo.
Continued to amass encouraging safety and efficacy data from the Phase 1/2 STAAR study of isaralgagene civaparvovec for Fabry disease.
Advanced neurology-focused preclinical pipeline, including data from novel delivery capsid, STAC-BBB.
Forward Guidance
Sangamo expects GAAP total operating expenses to be between $150 million and $170 million in 2024. Non-GAAP total operating expenses are expected to be between $125 million and $145 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...